Skip to main content

Table 2 Univariate analysis of risk factors affecting patient survival

From: Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study

Factor Variable Survival months (means ± SE) HR (95 % CI) p value
  Total 41.9 ± 32.4   
Patient-related Gender    
   Male 41.0 ± 32.1 1  
   Female 44.4 ± 33.0 0. 87 (0.73–1.03) 0.1074
  Age (years)    
   <40 47.1 ± 32.4 1  
   40–65 42.4 ± 32.7 1.15 (0.83–1.60) 0.4107
   ≥ 65 39.6 ± 31.6 1.32 (0.94–1.87) 0.1123
  Body mass index (kg/m2)    
   <18.5 42.1 ± 33.5 1  
   18.5–20 36.5 ± 29.2 1.13 (0.86–1.49) 0.3774
   20–24 42.5 ± 30.9 0.91 (0.75–1.10) 0.3137
   ≥ 24 42.8 ± 32.1 0.95 (0.77–1.17) 0.6183
  Comorbidity    
   No 41.6 ± 32.1 1  
   Yes 43.9 ± 34.6 0.93 (0.72–1.21) 0.5909
  Family history    
   No 41.3 ± 32.5 1  
   Yes 44.4 ± 32.0 0.80 (0.66–0.98) 0.0286
  Fibrinogen (g/L)    
   ≤ 4 45.7 ± 32.6 1  
   >4 30.8 ± 28.9 1.78 (1.49–2.11) < 0.0001
  Carcinoembryonic antigen    
   <5 43.4 ± 29.3 1  
   ≥ 5 31.7 ± 29.1 1.82 (1.38–2.38) < 0.0001
  Carbohydrate antigen 19-9    
   <37 43.2 ± 32.6 1  
   ≥ 37 26.4 ± 24.6 1.84 (1.44–2.35) < 0.0001
Tumor-related Tumor location    
   Lower 47.4 ± 32.7 1  
   Upper 34.2 ± 30.3 1.83 (1.50–2.23) < 0.0001
   Medium 30.7 ± 28.7 2.03 (1.70–2.42) < 0.0001
  Tumor size (cm)    
   <5 58.5 ± 30.0 1  
   ≥ 5 31.5 ± 29.4 3.29 (2.75–3.94) < 0.0001
  Multi-organ involvement    
   No 42.7 ± 32.3 1  
   Yes 24.3 ± 28.5 2.27 (1.68–3.07) < 0.0001
  Multifocal    
   No 44.4 ± 32.0 1  
   Yes 55.8 ± 28.5 0.67 (0.38–1.19) 0.1721
  Gross morphology    
   Flat 34.0 ± 36.0 1  
   Uplift 47.4 ± 33.1 0.56 (0.41–0.76) 0.0003
   Ulcerative 55.0 ± 32.3 0.42 (0.31–0.59) < 0.0001
   Infiltration ulcerative 40.8 ± 30.8 0.71 (0.57–0.90) 0.0037
   Diffuse infiltration 30.4 ± 29.1 1.09 (0.77–1.55) 0.6112
  T stage    
   1 44.8 ± 37.0 1  
   2 64.1 ± 27.4 0.35 (0.25–0.51) < 0.0001
   3 41.2 ± 30.4 1.20 (0.94–1.52) 0.1397
   4 31.7 ± 28.8 1.80 (1.42–2.27) < 0.0001
  N stage    
   N0 52.6 ± 33.4 1  
   N1 53.0 ± 31.2 1.12 (0.87–1.45) 0.3837
   N2 35.6 ± 29.7 2.36 (1.91–2.92) < 0.0001
   N3 23.8 ± 23.0 3.72 (3.06–4.53) < 0.0001
  Metastasis    
   No 44.1 ± 32.2 1  
   Yes 8.7 ± 7.7 5.75 (4.48–7.38) < 0.0001
  TNM    
   1 70.2 ± 25.2 1  
   2 56.4 ± 29.6 4.45 (2.80–7.07) < 0.0001
   3 28.6 ± 26.5 15.14 (9.76–23.49) < 0.0001
   4 8.8 ± 7.7 50.32 (30.71–82.46) < 0.0001
  Differentiation    
   Poor 33.0 ± 31.1 1  
   Medium 55.0 ± 30.3 0.38 (0.30–0.48) < 0.0001
   Signet ring 47.5 ± 30.5 0.49 (0.30–0.82) 0.0058
   Mucus 49.8 ± 31.5 0.58 (0.39–0.86) 0.0064
   Papillary 45.1 ± 32.6 0.54 (0.20–1.44) 0.2174
   Mixed or other 44.0 ± 32.2 0.64 (0.53–0.76) < 0.0001
Operation-related Operation time (min.)    
   ≤ 150 43.3 ± 32.9 1  
   >150 40.3 ± 31.8 1.17 (1.01–1.36) 0.0361
  Mode of lymph node dissection   
   Radical 52.2 ± 30.8 1  
   Non-radical 18.8 ± 20.4 4.74 (4.00–5.62) < 0.0001
   Palliative 7.2 ± 6.8 12.21 (9.52–15.67) < 0.0001
  Cleared lymph node number    
   <15 40.5 ± 33.2 1  
   ≥ 15 43.6 ± 31.3 0.81 (0.70–0.95) 0.0072
  Intraoperative blood loss (ml)   
   ≤ 200 44.1 ± 32.6 1  
   >200 31.7 ± 29.4 1.61 (1.35–1.93) < 0.0001
  Blood transfusion    
   No 44.6 ± 32.3 1  
   Yes 33.4 ± 31.0 1.64 (1.39–1.93) < 0.0001